Developmental and epileptic encephalopathy, 14
MONDO:0013989Any early infantile epileptic encephalopathy in which the cause of the disease is a mutation in the KCNT1 gene.
Also known as: KCNT1-related epilepsy, DEE14, EIEE14, KCNT1 early infantile epileptic encephalopathy, developmental and epileptic encephalopathy 14, early infantile epileptic encephalopathy caused by mutation in KCNT1, epileptic encephalopathy, early infantile, 14, epileptic encephalopathy, early infantile, type 14
20 clinical trials for this condition and its sub-types, 3 tagged with Developmental and epileptic encephalopathy, 14 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for kids with rare epilepsy: first human trial launches
Disease control Recruiting nowThis study tests a new medicine (S230815) for children aged 2-12 with a rare, severe epilepsy caused by changes in the KCNT1 gene. The goal is to see if the drug is safe and can help control seizures. About 20 children will take part, receiving the drug through a spinal injection…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for kids with rare seizure disorder: drug trial launches
Disease control Recruiting nowThis study tests an experimental drug called ABS-1230 in children and young adults (ages 1 month to under 22 years) with a rare epilepsy caused by changes in the KCNT1 gene. The goal is to see if the drug is safe and can reduce the number of seizures compared to a placebo. Partic…
Phase 2 • Sponsor: Actio Biosciences, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New epilepsy drug candidate enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage trial is testing a new drug called ABS-1230 in 74 healthy adults to see if it is safe and how the body processes it. The drug is being developed for a rare type of epilepsy caused by changes in the KCNT1 gene. Participants will receive either the drug or a placeb…
Phase 1 • Sponsor: Actio Biosciences, Inc. • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC